StartsidaJ7Z • FRA
add
Jazz Pharmaceuticals PLC
Föregående stängning
125,70 €
Dygnsintervall
125,55 € - 125,55 €
Årsintervall
92,40 € - 139,55 €
Börsvärde
8,21 md USD
Genomsnittlig volym
25,00
P/E-tal
-
Direktavkastning
-
Primär börs
NASDAQ
Aktuellt
Ekonomi
Resultaträkning
Intäkter
Nettoinkomst
| (USD) | dec. 2024info | Förändring Y/Y |
|---|---|---|
Intäkter | 1,09 md | 7,53 % |
Rörliga kostnader | 768,69 mn | 9,42 % |
Nettoinkomst | 191,12 mn | 102,98 % |
Nettovinstmarginal | 17,56 | 88,82 % |
Vinst per aktie | 6,60 | 31,47 % |
EBITDA | 396,98 mn | 0,82 % |
Giltig skattesats | −43,48 % | — |
Balansräkning
Totala tillgångar
Totala ansvarsskyldigheter
| (USD) | dec. 2024info | Förändring Y/Y |
|---|---|---|
Kontanta och kortsiktiga investeringar | 2,99 md | 83,66 % |
Totala tillgångar | 12,01 md | 5,43 % |
Totala ansvarsskyldigheter | 7,92 md | 3,42 % |
Totala tillgångar | 4,09 md | — |
Utestående aktier | 60,73 mn | — |
P/B | 1,86 | — |
Avkastning på tillgångar | 4,71 % | — |
Avkastning på kapital | 5,54 % | — |
Kassaflöde
Förändring i nettokassa
| (USD) | dec. 2024info | Förändring Y/Y |
|---|---|---|
Nettoinkomst | 191,12 mn | 102,98 % |
Kontanter från verksamhet | 398,58 mn | 138,19 % |
Kontanter från investering | −193,29 mn | −289,87 % |
Kontanter från finansiering | −8,28 mn | 91,75 % |
Förändring i nettokassa | 194,73 mn | 14,13 % |
Fritt kassaflöde | 466,32 mn | 470,30 % |
Om
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States. One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia
Grundades
2003
Hemsida
Anställda
2 800
